An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

NCT00121732 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Malignancies, Cancer

Interventions

DRUG: E7974
DRUG: E7974

Sponsor

Eisai Inc.